The effect of in-vitro granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment of neutrophils, monocytes or monocyte-derived macrophages (MDM) on candidacidal activity was tested. Synergy of effector cells with fluconazole (FCZ) for enhanced killing was also investigated. Incubation of neutrophils with GM-CSF 0.67 pg/L plus Candida albicans Sh27 for 24 h significantly increased candidacidal activity (36% versus 74%). Synergy with FCZ for killing was also significantly increased from 93% to 97% when neutrophils were incubated with GM-CSF. Monocytes cultured with GM-CSF and C. albicans for 24 h had significantly increased fungistatic activity compared to controls and synergy with FCZ for killing was significantly enhanced from 40% to 59%. Monocytes cultured for 3 days with GM-CSF had increased fungistatic activity compared to control MDM and showed synergy with FCZ for significantly enhanced killing (46%) compared to control MDM (12%).
Introduction
The molecular biology and functions of granulocytemacrophage colony-stimulating factor (GM-CSF) have been described by Metcalf [ 11. GM-CSF purified from mitogen-stimulated human T cells was shown to stimulate neutrophil function [2, 31. GM-CSF produced by recombinant DNA technology has been used clinically in AIDS patients [4, 51. Treatment of neutrophils or monocytes in vitro with rhGM-CSF increased their fungicidal activity for Candida albicans [6, 71; this was associated with enhanced superoxide anion production [ 81.
A recent study reported that fluconazole, a triazole that is only fungistatic for C. albicans showed synergy with human neutrophils, monocytes or monocyte-derived macrophages (MDM) for increased candidacidal activity [9, 101. Those results helped to explain the curative efficacy of fluconazole in vivo. The present study postulates that if GM-CSF-treated neutrophils, monocytes or MDM have augmented fungicidal activity, they should also show synergy with fluconazole for greater candidacidal activitiy compared to controls.
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Materials and methods

Candida albicans
C. albicans isolate Sh27 (ATCC 56882) and clinical isolates 94-159 and 94-186, susceptible to fluconazole (MIC < 0.5 mg/L) [9, 101 were used in these experiments. Yeast cells were grown on blood agar at 35°C for 48 h. Yeast cells were washed in saline, diluted, counted and suspended in RPMI-1640 containing penicillin 100 000 U/L, streptomycin 100 mg/L and fresh fi-ozen human serum (HS) 10% (5% in some experiments) (CTCM). Dilutions of the suspension were plated on blood agar plates in quadruplicate at time zero to determine the number of cfu in the inoculum.
Effector cells
Polymorphonuclear neutrophil leucocytes (PMNL) and peripheral blood mononuclear cells (PBMC) were isolated from heparinised blood by dextran-70 (6%) sedimentation followed by density gradient centrifugation on Histopaque 1077 (Sigma). PMNL were suspended to 2 X 106/ml in CTCM and dispensed 0.1 ml per microtest plate well (Corning #25860, Corning, N Y , USA). PBMC at 5 X 106/ml of CTCM with or without GM-CSF were dispensed 0.1 ml per microtest well (half area wells, Corning #25870) then incubated for 2 h at 37°C in CO2 5% in air in a CO2 incubator. After incubation, non-adherent cells were aspirated and the monolayer was washed once with RPMI-1640. In some experiments, quadruplicate sets of adherent cells (monocytes) were incubated in CTCM with or without GM-CSF for 3 days to obtain monocyte-derived macrophages (MDM).
GM-CSF
Recombinant human GM-CSF, Leukine (Sargramostin), was produced and supplied by Immunex Corp., Seattle, WA, USA. GM-CSF (1.5 X lo8 IU/mg) was diluted to 7.5 X lo5 IU (5mg/L) in RPMI-1640 and 0.1-ml portions were stored at -80°C.
Fluconazole
Fluconazole (FCZ) was supplied by Pfizer, Groton, CT, USA. FCZ powder was dissolved in distilled water at 2 g/L and stored at 4°C. Desired dilutions were made from the FCZ stock in RPMI-1640.
Effector cell assays
Effector cell cultures were challenged with 0.1 ml of a suspension of yeast cells in CTCM. Some sets of quadruplicate cultures received 0.01 ml of an appropriate dilution of GM-CSF. Other sets of quadruplicate cultures received 0.01 ml of FCZ to give a final concentration of 1 mg/L of both GM-CSF and FCZ. After incubation for 24 h at 37°C in COz 5%, cultures were harvested with distilled water to lyse human cells and release yeast cells. Appropriate dilutions of harvested material were plated on blood agar, colony counts were made after incubation for 48 h at 35"C, and cfu/culture were calculated.
Quantitative analysis
Human serum (10%) in RPMI-1640 inhibits the growth of C. albicans by > 90% compared to growth in RPMI-1640 alone [9] . Typical morphology of growth in CTCM was short budding pseudohyphae. In co-cultures with effector cells no extracellular growth of C. albicans was evident. When growth in CTCM was harvested, pelleted and examined by microscopy, 92% Where killing occurred, e.g., experimental cfu inoculum cfu, fungistasis was defined as 100%. Student's t test was used for statistical analysis of data and significance was set at p < 0.05.
Results
Effect of GM-CSF on PMN
Incubation of PMNL with GM-CSF (0.67 or 3.33 pg/L) and C. albicans for 24 h resulted in enhanced killing (p < 0.01) compared to killing in PMNL cultures without GM-CSF, 74% and 68% versus 36% (Table 1) . As previously reported, PMNL showed synergy with FCZ for significantly increased killing of C. albicans and that was confirmed here, e.g., 36% versus 93% killing. Moreover, PMNL in the presence of GM-CSF showed synergy with FCZ to a significantly greater extent for killing than did PMNL plus FCZ, 4.8 X 10' (SD 0.9 X lo2) and 3.4 X 10' (SD 1 X 10') cfu versus 8.1 X 10' (SD 1.3 X 10') cfu (Table 1) .
In a suboptimal system in which CTCM contained only 5% human serum, PMNL failed to kill C. albicans in the 24-h assay. The effect of GM-CSF (3.33 pg/L) on PMNL was amplified in this system and killing increased from 0% to 75% (Table 2) . Under these suboptimal conditions, PMNL and FCZ showed synergy only for a low level of killing (17%).
On the other hand, PMNL with GM-CSF showed synergy with FCZ for a significantly increased level of killing, e.g., 17% versus 98% (Table 2) . 
Effect of GM-CSF on monocytes
When monocytes were co-cultured with GM-CSF (0.67 ,ug/L) and C. albicans for 24 h, growth was inhibited compared to growth in monocyte cultures without GM-CSF (p < 0.01) ( Table 3) . As previously reported, monocytes showed synergy with FCZ for killing C. albicans and here killing was 40%; monocytes with GM-CSF and FCZ caused significantly increased killing, 59% (Table 3) . Similar results were obtained in a second experiment.
Effect of GM-CSF on MDM
When monocytes were cultured for 3 days in CTCM containing human serum 10% with or without GM-CSF (0.67 ,ug/L) both types of MDM were highly hngistatic, but not fungicidal for C. albicans (Table 4) . It can be noted that MDM from GM-CSF cultures caused increased fungistasis, 1.9 X lo3 (SD 0.2 X lo3) cfu versus 3.8 X lo3 (SD 0.3 X lo3) cfu. MDM showed synergy with FCZ for killing C. albicans (12%). Moreover, synergic killing increased to 46% when GM-CSF MDM were cultured with FCZ and C. albicans (Table 4) .
When monocytes were cultured under suboptimal conditions, e.g., CTCM containing human serum 5%, MDM from GM-CSF cultures had significantly in- tKillPg by monocytes + FCZ compared to killing by moncytes + GM-CSF + FCZ, p < 0.01. **. +See footnote to Table I . creased fungistatic activity compared to control MDM, e.g., 1.9 X lo3 (SD 0.6 X lo3) versus 4.8 X lo3 (SD 1.7 X lo3) cfu ( (Table 5) .
GM-CSF enhances the antiin a 24-h assay. Richardson et with a different experimental design [6] ; adherent PMNL were pretreated with GM-CSF for 1 h, then challenged for 3 h and enhanced killing of C. albicans was measured as reduced survival of the inoculum.
PMNL activated by GM-CSF have increased capacity to show synergy with FCZ, resulting in significantly enhanced killing of C. albicans compared to controls.
Sixty percent of C. albicans yeast cells are killed by monocytes in 2-h assays [ 111. Depending on inoculum size and donor variations it has been found that in 24-h assays there can be reduction of inoculum cfu or, as reported here, fungistasis. We postulate that in 24-h co-cultures, yeast cells surviving the initial killing multiply so that the number of cfu at 24 h is greater than at the time of inoculation.
The present study showed that co-culture of monocytes with GM-CSF for 24 h enhanced their fungistatic activity for C. albicans. Smith et al. used a different protocol and an indirect method for measuring anti fungal activity and reported similar results [7] . They exposed monocytes to GM-CSF (500 U/ml) for 14 h, challenged the monocytes with 3H-leucine-labelled C. albicans for 4 h and measured increased anti fungal activity by H-leucine release. Moreover, the present study demonstrated that GM-CSF induced increased ability of monocytes to show synergy with FCZ for killing C. albicans compared to controls.
While others have reported that GM-CSF activation of MDM increased antimicrobial activity against Mycobacterium avium, Leishmania donovani and Trypanosoma cruzi, this study reports for the first time that GM-CSF increased the fungistatic activity of MDM for C. albicans [12-141. A previous study demonstrated that MDM shows synergy with FCZ for killing C. albicans [lo] . This study confirms those results and demonstrates that GM-CSF treatment augments the capacity of MDM to show synergy with FCZ for increased candidacidal activity.
These results provide a rationale for combination therapy with GM-CSF and fluconazole in the treatment of fungal infection. 
